Year-end Sale % OFF 
Abstract
Purpose: To develop and validate a new, simple, sensitive, rapid, cost-effective and accurate reverse phase-high performance liquid chromatography (RP-HPLC) method for the determination of aprepitant (APT) in capsule dosage form.Methods: The method developed for the determination of APT in capsule formulation involved using RP-HPLC which incorporated a C18 column 250 x 2.5 mm i.d, 5 μm particle size, in isocratic mode, with mobile phase comprising of methanol: water in the ratio of 90:10 (v/v). The flow rate was 1 mL/min and the detection was monitored at 220 nm. The total run time was 10 min and the column was maintained at ambient temperature.Results: APT was eluted in the given mobile phase with a retention time (tr) of 4.473 min. The linearity for the quantification of APT was 0.1 - 10 μg/mL (R2 =0.989, Y= 33032x + 71501) with coefficients of variation (based on mean peak area for six replicate injections) in the range 0.04 to 0.132. The limits of detection and of quantification were 0.028 and 0.094 μg/mL, respectively. Recovery of the method was 99.56 - 100.5 % while the relative standard deviation (RSD) of intra-day and inter-day precision was 0.85 and 1.05, respectively. System precision and method precision were 0.013 and 1.400 %, respectively. The specificity data of the proposed method indicated that excipients in the capsules did not interfere with the drug peak. Furthermore, the well-shaped peaks buttressed the specificity of the method.Conclusion: The proposed RP-HPLC method is simple, sensitive, rapid, cost-effective and accurate for the determination of APT in both bulk materials and pharmaceutical dosage forms.Keywords: Aprepitant, RP-HPLC, Isocratic, Pharmaceutical dosage forms, Analysis, Validation
Highlights
Aprepitant (APT) is substance P/neurokinin 1 (NK1) receptor antagonist, and chemically, it is 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis phenyl]ethoxy]-3-(4-fluorophenyl)-4morpholinyl]methyl]-1,2dihydro-3H-1,2,4triazol-3-one (Fig 1).It is a white to off-white crystalline solid, with a molecular weight of 534.43 and empirical formula C23H21F7N4O3
It is a selective highaffinity antagonist of human substance P/neurokinin 1 (NK1) receptors and has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, which are the targets of existing therapies for chemotherapy-induced nausea and vomiting (CINV) as well as postoperative nausea and vomiting (PONV) [1]
The drug was eluted in the given mobile phase at a short retention time of 4.313 min
Summary
It is a white to off-white crystalline solid, with a molecular weight of 534.43 and empirical formula C23H21F7N4O3. It is a selective highaffinity antagonist of human substance P/neurokinin 1 (NK1) receptors and has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, which are the targets of existing therapies for chemotherapy-induced nausea and vomiting (CINV) as well as postoperative nausea and vomiting (PONV) [1]. APT has been shown in animal models to inhibit emesis induced by cytotoxic chemotherapeutic agents, such as cisplatin, via central actions. Animal and human studies show that APT augments the antiemetic activity of the 5-HT3 receptor antagonist, ondansetron, and the corticosteroid, dexamethasone, and inhibits both the acute and delayed phases of cisplatin-induced emesis
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
